Johnson Financial Group Upped Its Holding in Exxon Mobil (XOM) as Stock Value Declined; As Teva Phrm Ind LTD Adr (TEVA) Valuation Declined, Shareholder Kempner Capital Management Trimmed Position

Exxon Mobil Corporation (NYSE:XOM) Logo

Kempner Capital Management Inc decreased its stake in Teva Phrm Ind Ltd Adr (TEVA) by 63.06% based on its latest 2017Q4 regulatory filing with the SEC. Kempner Capital Management Inc sold 131,773 shares as the company’s stock declined 11.04% with the market. The institutional investor held 77,184 shares of the major pharmaceuticals company at the end of 2017Q4, valued at $1.46M, down from 208,957 at the end of the previous reported quarter. Kempner Capital Management Inc who had been investing in Teva Phrm Ind Ltd Adr for a number of months, seems to be less bullish one the $17.38B market cap company. The stock increased 0.29% or $0.05 during the last trading session, reaching $17.09. About 8.31M shares traded. Teva Pharmaceutical Industries Limited (NYSE:TEVA) has declined 49.50% since March 31, 2017 and is downtrending. It has underperformed by 61.05% the S&P500.

Johnson Financial Group Inc increased its stake in Exxon Mobil Corp (XOM) by 8.57% based on its latest 2017Q4 regulatory filing with the SEC. Johnson Financial Group Inc bought 6,447 shares as the company’s stock declined 12.23% with the market. The institutional investor held 81,704 shares of the integrated oil company at the end of 2017Q4, valued at $6.83M, up from 75,257 at the end of the previous reported quarter. Johnson Financial Group Inc who had been investing in Exxon Mobil Corp for a number of months, seems to be bullish on the $316.27 billion market cap company. The stock increased 2.47% or $1.8 during the last trading session, reaching $74.61. About 14.88 million shares traded. Exxon Mobil Corporation (NYSE:XOM) has declined 9.29% since March 31, 2017 and is downtrending. It has underperformed by 20.84% the S&P500.

Among 26 analysts covering Exxon Mobil (NYSE:XOM), 10 have Buy rating, 6 Sell and 10 Hold. Therefore 38% are positive. Exxon Mobil has $104 highest and $20 lowest target. $81.59’s average target is 9.36% above currents $74.61 stock price. Exxon Mobil had 91 analyst reports since July 22, 2015 according to SRatingsIntel. The stock of Exxon Mobil Corporation (NYSE:XOM) earned “Hold” rating by BMO Capital Markets on Monday, May 1. The rating was maintained by Piper Jaffray on Thursday, August 24 with “Hold”. As per Thursday, August 20, the company rating was upgraded by Vetr. Piper Jaffray maintained Exxon Mobil Corporation (NYSE:XOM) rating on Tuesday, January 23. Piper Jaffray has “Hold” rating and $89.0 target. The stock has “Underperform” rating by Credit Suisse on Monday, May 2. Jefferies maintained the stock with “Hold” rating in Tuesday, August 29 report. Barclays Capital upgraded Exxon Mobil Corporation (NYSE:XOM) rating on Monday, October 12. Barclays Capital has “Equal-Weight” rating and $85 target. Piper Jaffray maintained Exxon Mobil Corporation (NYSE:XOM) rating on Tuesday, November 21. Piper Jaffray has “Hold” rating and $81.0 target. The rating was maintained by Jefferies with “Hold” on Thursday, October 19. The firm earned “Hold” rating on Tuesday, October 3 by Jefferies.

Since December 11, 2017, it had 0 insider buys, and 4 insider sales for $3.42 million activity. Wascom Dennis G also sold $200,293 worth of Exxon Mobil Corporation (NYSE:XOM) shares. $606,082 worth of stock was sold by Milton Bryan W on Tuesday, December 12. Shares for $1.62M were sold by Corson Bradley W on Monday, December 11.

Investors sentiment decreased to 0.84 in 2017 Q4. Its down 0.01, from 0.85 in 2017Q3. It worsened, as 48 investors sold XOM shares while 819 reduced holdings. 123 funds opened positions while 603 raised stakes. 2.17 billion shares or 1.92% more from 2.13 billion shares in 2017Q3 were reported. Chesapeake Asset Limited Liability reported 1.66% stake. Sandy Spring Commercial Bank has 134,134 shares for 1.02% of their portfolio. Godsey Gibb Assocs reported 18,622 shares stake. Rfg Advisory Limited Liability has 0.53% invested in Exxon Mobil Corporation (NYSE:XOM) for 13,222 shares. Fulton Breakefield Broenniman Ltd accumulated 0.79% or 56,571 shares. Miller Invest Management Limited Partnership has 0.25% invested in Exxon Mobil Corporation (NYSE:XOM). Moreover, Bnp Paribas Arbitrage has 0.31% invested in Exxon Mobil Corporation (NYSE:XOM) for 2.14M shares. Fifth Third Savings Bank holds 2.09 million shares. Fort Point Cap Prtnrs reported 0.87% in Exxon Mobil Corporation (NYSE:XOM). Blb&B Advsrs Ltd holds 2.08% or 173,969 shares in its portfolio. Brinker Capital has 14,933 shares for 0.05% of their portfolio. Alpine Woods Investors Ltd Liability Co holds 0.13% of its portfolio in Exxon Mobil Corporation (NYSE:XOM) for 30,911 shares. Barrow Hanley Mewhinney Strauss Ltd Limited Liability Company accumulated 0% or 16,400 shares. Redmond Asset Limited Liability Company, a Virginia-based fund reported 7,161 shares. Atria Invs Ltd Llc accumulated 0.39% or 92,717 shares.

Johnson Financial Group Inc, which manages about $8.40 billion and $816.52 million US Long portfolio, decreased its stake in Johnson Outdoors Inc Cl A (NASDAQ:JOUT) by 43,200 shares to 1.83M shares, valued at $113.54M in 2017Q4, according to the filing. It also reduced its holding in The Mosaic Company (NYSE:MOS) by 12,881 shares in the quarter, leaving it with 2,175 shares, and cut its stake in Walmart Stores Inc (NYSE:WMT).

Analysts await Teva Pharmaceutical Industries Limited (NYSE:TEVA) to report earnings on May, 10. They expect $0.64 EPS, down 37.86% or $0.39 from last year’s $1.03 per share. TEVA’s profit will be $650.79M for 6.68 P/E if the $0.64 EPS becomes a reality. After $0.91 actual EPS reported by Teva Pharmaceutical Industries Limited for the previous quarter, Wall Street now forecasts -29.67% negative EPS growth.

Kempner Capital Management Inc, which manages about $421.42 million and $160.10M US Long portfolio, upped its stake in Merck & Co. Inc. (NYSE:MRK) by 44,827 shares to 65,886 shares, valued at $3.71 million in 2017Q4, according to the filing.

Among 35 analysts covering Teva Pharma (NYSE:TEVA), 9 have Buy rating, 8 Sell and 18 Hold. Therefore 26% are positive. Teva Pharma has $86 highest and $8 lowest target. $28.73’s average target is 68.11% above currents $17.09 stock price. Teva Pharma had 149 analyst reports since July 21, 2015 according to SRatingsIntel. As per Monday, February 12, the company rating was upgraded by Credit Suisse. The firm has “Equal-Weight” rating given on Monday, August 7 by Barclays Capital. Cantor Fitzgerald upgraded the shares of TEVA in report on Friday, December 22 to “Hold” rating. The stock has “Hold” rating by Mizuho on Wednesday, November 29. As per Friday, December 15, the company rating was upgraded by Goldman Sachs. The stock of Teva Pharmaceutical Industries Limited (NYSE:TEVA) earned “Buy” rating by Deutsche Bank on Wednesday, November 16. The stock of Teva Pharmaceutical Industries Limited (NYSE:TEVA) earned “Hold” rating by Deutsche Bank on Friday, November 3. The stock has “Neutral” rating by BTIG Research on Thursday, January 18. Jefferies reinitiated Teva Pharmaceutical Industries Limited (NYSE:TEVA) on Friday, October 30 with “Buy” rating. The company was maintained on Friday, January 26 by Leerink Swann.

Exxon Mobil Corporation (NYSE:XOM) Institutional Positions Chart